Post on 16-Aug-2015
transcript
Engaging Adaptable Hybrid Ecosystems to commercialize nascent technologies-A perspective on Nanobiotechnologycommercialization
Bhuvaneashwar Subramanian, Program Manager,Healthcare and Life Sciences Vertical Intelligence PracticeGlobal Analytics, Corporate Strategy and AlliancesHewlett Packard CompanyEmail : bhuvaneashwar.subramanian@hp.com
Key Themes Covered
Innovation Ecosystems and Their Limitations in Theory
Introduction to the AHE theory The Nanobiotechnology Example Assessment of ecosystems across US,
Australia and Malaysia Future Directions
Innovation ecosystems : An organized system of actors and agencies aimed at facilitating innovation through dynamic exchange of knowledge
Governments
AcademiaIndustryIndividual
Organizations
Nations
People
Industries
Current models of innovation focus myopically on improving the competitive advantage of nations
MODEL 1: NATIONAL INNOVATION SYSTEMS(NIS)
Policy
• Driven by governments
Structure
• Core Environments
• Supporting Entities
• Knowledge Flows
Objective
• Improving economic performance through regional innovation activity
Current models of innovation focus myopically on improving the competitive advantage of nations
MODEL 2: TRIPLE HELIX MODEL(THM)
Policy
• Primarily driven by universities through tech licensing and spinoffs
Structure
• University driven
• Collaboration between three institutions
• Alternative positioning approaches
Objective
• Create a knowledge based society to improve regional economic performance
Existing innovation models are challenged on three fronts-
Localization of Resources
NIS focuses on localization of resourcesTHM does not discuss how interchangeability of resources could occur
Lack of Pervasiveness
Both theories do not sufficiently address the pervasiveness of the ecosystems outside national boundaries
Adaptability to Changing Innovation Dynamics
The theories do not suitably provide for trends such as reverse innovation, open innovation and crowdsourcing
The Adaptable Hybrid Ecosystem Theory Builds on These Challenges to fundamentally call out -
An inclusive innovation environment that is sustained by dynamic and evolutionary interactions between temporal global alliances of industry, academia and universities, guided by the facilitatory powers of governments through bilateral agreements
The theory implies 4 fundamental paradigm shifts that encompass the wave of globalization
View Global Consumers
as Need Based
Clusters
Viewing Regions as Centers of
Competenceand Markets
Coexistence of multiple innovation
models
1 2 3
Governments as Facilitators
4
Nanobiotechnology : A convergence of nanotechnology and biotechnology
Atomic Force Microscopy
Targeted Cancer Therapeutics(paclitaxel,abraxane)
Drug DeliveryMEMS based molecular diagnostics
A view of the nanobiotechnology market and challenges
US$19Bn in 2012
US$200Mn/yrTo the NNI
65%
20%
15%
Intellectual Investment
United StatesEuropeRest of World
40 Nanobio-
technologyproducts
Key Challenges for the Industry
• FDA approval of nanobiotechnologyproducts is stringent and is mostly driven towards topical applications
•Nascent nature of the field shows poor proof of concepts and cross application of patents across other disciplines prevents commercialization
•Venture capitalists are looking for quick exit only to recover investments after first technology licensing
•Less than 40 products commercialized•Limited engagement with big pharma
Lack of suitable
technology transfer
initiatives
Lack of sustained venture capital
interest
Regulatory and socio-
ethical concerns
Lack of sufficient proof of
concepts and patent wars
Instances of Various Paradigms of AHE play out across nanobiotechnology commercialization activities across US, Australia and Malaysia
Viewing Customers as Need Based Clusters1
Nanomedicine Roadmap Initiative in collaboration with Private Pharma Majors
Open Innovation Initiatives to facilitate drug discovery and development including nanodrug delviery systems
Gamification platforms to address protein folding challenges on a global scale
United States of America
Paradigm Shift Implications for the AHE in US, Malaysia and Australia
Regions as Centers of Competenceand Markets
2
MALAYSIA AUSTRALIA
MOSTI Invests US$800 Million for leveraging competence in nanotechnology for MEMS design
Collaboration with US leading to FDI of US$45 Billion for tech
know how and training US$1 billion investment into the
Biotech Cluster in Malaysia by Pharma and Life Sciences Majors
to develop therapeutics and reach out to the APJ region
Australian and EU collaboration program-FEAST for nanobioresearch and commercialization Collaboration between private
entities in Australia and China for technology commercialization
Paradigm Shift Implications for the AHE in US, Malaysia and Australia
Multiple Innovation Models Dependent Upon Business Need and Maturity
3
Formation of Precompetitive Alliances such as the NanomedicinesAlliance for rapid nanobiotherapeutic commercialization
Technology licensing agreements between nanotechnology startups and pharma majors for molecular diagnostics
Paradigm Shift Implications for the AHE in US, Malaysia and Australia
Governments as Facilitators of Innovation 4
International Dialogue on Responsible Research and Development of Nanotechnology,
Foresight Guidelines on Molecular Nanotechnology International Consensus Standards TheAustralia Group have engaged separately in formal and informal
ways, to facilitate international policies for regulation of nanotechnology
The facilitation is dynamic ranging from clear directive focussed to creating environments and engaging as an advisor based on the maturity of the industry
UNITED STATES , EU & AUSTRALIA
Structured and Unstructured Environments Equally Facilitate Commercialization of Nanobiotechnology
UNITED STATES AUSTRALIA MALAYSIA
• Central Governance(NNI)
• Industry Consortium Driven
• Industry Consortium• Driven+Government
Driven
• Government directs programs
•Drives International Riskmanagement collaborations for commercialization throughIRC
•Government serves as afacilitator with focus
only on creating awarnesson safety aspects.
• Government plays an advisory role that handholds until certain time of maturity
• NNI and NIH run competitive grant programs for international collaborative projects and SME development.
• Private sector focused on international linkages for innovation
• ARC and ARCNN facilitate international research collaborations in nanobiotech
• Autonomous industry bodies such as ANA and ANMA facilitate industry linkages and collaborations
• MOSTI facilitates collaborations and HRD development
• Industry bodies such as BiotechCorp engage in partnering with global players in biotechnology and nanobiotechnology
Conclusion
The AHE model offers a perspective on how nascent technologies could be commercialized across global boundaries
It explores the possibilities of driving innovation by addressing key paradigm shifts that serve as pillars for its implementation
Next Steps
Research is needed to understand how knowledge flows across the entities may be governed so as to address the paradigms discussed
Research on impact of open innovation and new business models on knowledge flows and capacity development for innovation ecosystems in emerging markets
Viability of new business models and penetration of paradigms in emerging markets
THANK YOU
You can reach me at :bhuvaneashwar.subramanian@hp.com
oreashwarsubramanian@gmail.com